PILA PHARMA’s Post

Meet SOMAÍ Pharmaceuticals team Michael Sassano, George Bellow, Vasiliki K., and Anton Nakhodkin at the expopharm, which will take place on 27-30 September in Düsseldorf. We would happily talk with you at our booth 1B35 in Hall 1. If you are interested in scheduling a meeting to discuss potential collaborations with SOMAÍ, please schedule a meeting with our team by contacting Nádia Mendes Simões da Cruz or emailing hello@somaipharma.eu. #SOMAÍ #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews #medicalcannabisEU 

Strides Pharma gets USFDA nod for its drug to treat elevated phosphorous levels 💊What is the news buzz.? Strides Pharma Science Limited announced that their wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the drug to treat elevated phosphorous levels, from the USFDA. 💊What is the name of the drug.? Sevelamer Carbonate Tablets, 800 mg 💊What is the bioequivalent of this product.? According to the company the product is bioequivalent of Renvela Tablets, 800 mg, of Genzyme. 💊What is the market for this product.? According to the IMF Sevelamer Carbonate Tablets, 800 mg has a market size of ~US$ 181 Million. 💊Where will the product be manufactured ? The company has said that they will be manufactured at the company’s facility in Puducherry. I will provide the source of the article in the comment section below. By the way today is the 54th day of me deep diving into the pharmaceutical industry. I will be sharing insights from this industry on a regular basis. So please do follow me (Krishna Raj K) for such insights. #finance #Linkedin #India

The breakthrough of #GenerativeAI was a turning point for #pharma and #biopharma - changing the way medicines are discovered, developed, and delivered. 🔄 Hear from our CEO Raj Indupuri on why this advancement was the most consequential event of 2023 and how its impact will drive what's next for #ClinicalTrials, in Pharma's Almanac: https://lnkd.in/da3fd6kj

Exciting growth ahead for the Small Molecule Innovator CDMO market! Projected to soar from USD 45.4 billion in 2022 to USD 84.7 billion by 2032, with a CAGR of 6.6%. What are the driving factors for the growth? - Rising Demand for Outsourcing - Technological Advancements - Stringent Regulatory Requirements - Focus on Core Competencies - Pipeline of Small Molecule Drugs - Globalization Huge shoutout to companies Lonza, Catalent Pharma Solutions, Patheon (Thermo Fisher Scientific), Recipharm, Evonik, Cambrex, Alcami Corporation, Jubilant Pharmova Limited, Piramal Pharma Ltd, WuXi AppTec, FAREVA, Aenova Group, Siegfried, Curia, Symbiosis Pharmaceutical Services for being the major drivers in this growth. What other companies are making a huge difference in the small molecule space? Shout your company out in the comments and lets grow this list above! If you want to read more on this article, head over to PharmiWeb.com: Life Science News & Resources

Timelines for launching a new drug are intense. Why not get a head start? Herspiegel can give you a head start with our proven go-to-market model. Forged from 125+ pharma product launches. https://bit.ly/3umkI56 Download the whitepaper to read more. #pharma #biotech #pharmamarketing #druglaunch #gotomarket #AskHerspiegel

📌EVENT | UnConference by CataloniaBio & HealthTech Great event yesterday at the #UnConference organised by CataloniaBio & HealthTech! ➡ The event was focused on advanced therapies medicinal products (#ATMPs), and posed a great opportunity to debate about the ground-breaking therapeutic possibilities they offer and their significant role in the #pharmaceutical and #biotech industry. ➡ ASPHALION experts Núria Romero Carol and Oriol Penon, PhD attended the event, together with Christopher Mann, who joined one of the panel discussions about one of the challenges to be addressed: “How to improve #marketaccess and #regulatory barriers for solutions in #advancedtherapies?”. Better competitiveness of companies, improved market access and #regulatorypathway are key to get to increase the opportunity for patients to be treated with #noveltherapies and ensure #technological sovereignty and #supply. ➡ At Asphalion we are experts! Contact us for any information on ATMPs at: info@asphalion.com https://lnkd.in/dWRHwXSb #MeetTheExpert #RA #RegulatoryAffairs #AdvancedTherapiesMedicinalProducts #CataloniaBio #WeAreAsphalion #WeCare #KnowledgeFromExperience

🌟 Recent Pharma Industry Highlights 🌟 1. 🦠 Recce Pharmaceuticals Ltd's R327 triumphs over superbugs, showcasing powerful antimicrobial effects! 2. 🤝 Yuhan Corporation Corp collaborates with PROGEN to advance groundbreaking treatments! 3. 💉 Serum Institute of India Pvt. Ltd. strengthens its portfolio by acquiring Bilthoven Biologicals! 4. 🚀 Ascentage Pharma's Olverembatinib secures approval, marking a significant milestone! 💬 Join the Conversation!   Which news excites you the most? Share your thoughts below! 🗣️ 🔗 Stay tuned for more updates and exclusive content! #PharmaNow #PharmaNews #HealthcareInnovation #Partnerships #MedicalAdvancements #StayTuned

This year's conference theme is “Accelerate Drug Development through Scientific Innovation, Regulatory Convergence, and Global Partnership". I will be on a panel session with other industry leaders discussing ADC and RDC for Targeted Therapy. Schedule a meeting with me to discuss how we can simplify already a complex supply chain - bit.ly/3Lcq4WS #Biotech #Biotechnology #pharma #biopharma #Innovation #CRDMO #CDMO #drugdevelopment #drugmanufacturing #biomanufacturing #drugsubstance #drugproduct #Antibodydrugconjugates #antibodies #BsADCs #ADC #pharmaindustry #adcmanufacturing #contractmanufacturing #innovation #quality #atonbiotech 

Timelines for launching a new drug are intense. Why not get a head start? Herspiegel can give you a head start with our proven go-to-market model. Forged from 125+ pharma product launches. https://bit.ly/3umkI56 Download the whitepaper to read more. #pharma #biotech #pharmamarketing #druglaunch #gotomarket #AskHerspiegel

Thoughts on this? >> SK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing